Posts Tagged ‘development’
Viridis Energy Adds Renewable Energy Executive to its Board of Directors New …
Dec 14, 2011 (ACCESSWIRE-TNW via COMTEX) –
Vancouver, BC – December 14, 2011 – Viridis Energy Inc.
(“Viridis” or the “Company”)
/quotes/zigman/561044 CA:VRD
-2.70%
a “Cleantech” manufacturer and distributor of
alternative energy providing biomass fuel to global residential and
industrial markets, today announced that Vivek Rastogi, Vice President
of Abellon Energy, Inc. (“Abellon”) has joined its board of
directors.
Viridis and Abellon entered into a strategic alliance in August 2011
in which the two companies agreed to collaborate on the procurement
and supply of wood pellets and the proposed development of a
production facility in Monte Lake, BC. As part of the strategic
agreement, Abellon also agreed to make a direct investment into the
Company through participation of up to 10 percent of the private
placement the Company announced on December 2010, the terms of which
were amended in June 2011.
Mr. Rastogi joined Abellon its group companies in 2002 and is
presently based in Vancouver, BC where he oversees the company’s Clean
Energy business and Sustainable Development initiatives in the
Americas region. Upon earning graduate degrees in science, software
and post graduation in management from India, Mr. Rastogi embarked on
a career in business strategy, creating and managing business ventures
and international business across several developed and emerging
economies. His industry experience includes life sciences, clean and
renewable energy, agri-sciences, engineering and building construction
materials, food and beverage, and information technology.
Commenting on Mr. Rastogi’s appointment, Christopher Robertson,
Viridis’s CEO, said, Vivek adds a new dimension to our board of
directors. His diversified background in business development and
renewable energy resources will support Viridis’ expansion strategy
into overseas markets. His direct involvement in Abellon’s renewable
biomass energy endeavors should prove invaluable to Viridis as we add
alternative bio-waste fuel sources to our product line.”
---------------------------------------------------------------
|Company Contact: |Investor Contact:
|A AMichele Rebiere |A AYvonne L. Zappulla
|A AChief Financial Officer |A AManaging Director
|A AViridis Energy Inc |A AGrannus Financial
|A A905-847-5226 |Advisors, Inc.
|A Ainvestorinfo@viridisenergy.ca|A A212-681-4108
|A |A
| |AYvonne@GrannusFinancial.com
| |A
---------------------------------------------------------------
About Viridis Energy Inc.
Viridis Energy Inc.
/quotes/zigman/561044 CA:VRD
-2.70%
is a publicly traded,
“Cleantech” alternative energy company specializing in the
agricultural and wood waste biomass. Located in Vancouver, B.C.,
Viridis Energy operates Cypress Pacific Marketing and Okanagan Pellet
Company, two acquisitions in the wood pellet sector, thus providing
the company with vertical integration for distribution and
manufacturing.
For more information on Viridis Energy Inc. please refer to the
company website at
www.viridisenergy.ca
.
Forward-looking Statements
Certain statements in this release are forward-looking statements,
which reflect the expectations of management regarding the Company’s
future operations. Forward-looking statements consist of statements
that are not purely historical, including any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
statements are subject to risks and uncertainties that may cause
actual results, performance or developments to differ materially from
those contained in the statements. No assurance can be given that any
of the events anticipated by the forward-looking statements will occur
or, if they do occur, what benefits the Company will obtain from them.
These forward-looking statements reflect management’s current views
and are based on certain expectations, estimates and assumptions which
may prove to be incorrect. A number of risks and uncertainties could
cause our actual results to differ materially from those expressed or
implied by the forward-looking statements, including: (1) a continued
downturn in general economic conditions in North America and
internationally, (2) the inherent uncertainties associated with the
demand for biofuels, (3) the risk that the Company does not execute
its business plan, (4) inability to finance operations and growth (5)
inability to retain key management and employees, (6) ; an increase in
the number of competitors with larger resources, and (7) other factors
beyond the Company’s control. These forward-looking statements are
made as of the date of this news release and the Company intends to
update such forward looking information in the Company’s MDA in
the event that actual results differ materially from such
forward-looking statements contained herein. Additional information
about these and other assumptions, risks and uncertainties are set out
in the “Risks and Uncertainties” section in the Company’s
MDA filed with Canadian security regulators.
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
###
Copyright 2011 ACCESSWIRE-TNW
/quotes/zigman/561044
![]()
Add VRD to portfolio
CA:VRD

![]()
/quotes/zigman/561044
![]()
Add VRD to portfolio
CA:VRD

![]()
Viridis Energy Adds Renewable Energy Executive to its Board of Directors

VANCOUVER, BRITISH COLUMBIA, Dec 14, 2011 (MARKETWIRE via COMTEX) –
Viridis Energy Inc. (“Viridis” or the “Company”)
/quotes/zigman/561044 CA:VRD
-2.70%
(otcqx:VRDSF) a “Cleantech” manufacturer and distributor of
alternative energy providing biomass fuel to global residential and
industrial markets, today announced that Vivek Rastogi, Vice
President of Abellon Energy, Inc. (“Abellon”) has joined its board of
directors.
Viridis and Abellon entered into a strategic alliance in August 2011
in which the two companies agreed to collaborate on the procurement
and supply of wood pellets and the proposed development of a
production facility in Monte Lake, BC. As part of the strategic
agreement, Abellon also agreed to make a direct investment into the
Company through participation of up to 10 percent of the private
placement the Company announced on December 2010, the terms of which
were amended in June 2011.
Mr. Rastogi joined Abellon its group companies in 2002 and is
presently based in Vancouver, BC where he oversees the company’s
Clean Energy business and Sustainable Development initiatives in the
Americas region. Upon earning graduate degrees in science, software
and post graduation in management from India, Mr. Rastogi embarked on
a career in business strategy, creating and managing business
ventures and international business across several developed and
emerging economies. His industry experience includes life sciences,
clean and renewable energy, agri-sciences, engineering and building
construction materials, food and beverage, and information
technology.
Commenting on Mr. Rastogi’s appointment, Christopher Robertson,
Viridis’s CEO, said, Vivek adds a new dimension to our board of
directors. His diversified background in business development and
renewable energy resources will support Viridis’ expansion strategy
into overseas markets. His direct involvement in Abellon’s renewable
biomass energy endeavors should prove invaluable to Viridis as we add
alternative bio-waste fuel sources to our product line.”
About Viridis Energy Inc.
Viridis Energy Inc.
/quotes/zigman/561044 CA:VRD
-2.70%
is a publicly traded,
“Cleantech” alternative energy company specializing in the
agricultural and wood waste biomass. Located in Vancouver, B.C.,
Viridis Energy operates Cypress Pacific Marketing and Okanagan Pellet
Company, two acquisitions in the wood pellet sector, thus providing
the company with vertical integration for distribution and
manufacturing.
For more information on Viridis Energy Inc. please refer to the
company website at
www.viridisenergy.ca .
Forward-looking Statements
Certain statements in this release are forward-looking statements,
which reflect the expectations of management regarding the Company’s
future operations. Forward-looking statements consist of statements
that are not purely historical, including any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
statements are subject to risks and uncertainties that may cause
actual results, performance or developments to differ materially from
those contained in the statements. No assurance can be given that any
of the events anticipated by the forward-looking statements will
occur or, if they do occur, what benefits the Company will obtain
from them. These forward-looking statements reflect management’s
current views and are based on certain expectations, estimates and
assumptions which may prove to be incorrect. A number of risks and
uncertainties could cause our actual results to differ materially
from those expressed or implied by the forward-looking statements,
including: (1) a continued downturn in general economic conditions in
North America and internationally, (2) the inherent uncertainties
associated with the demand for biofuels, (3) the risk that the
Company does not execute its business plan, (4) inability to finance
operations and growth (5) inability to retain key management and
employees, (6) ; an increase in the number of competitors with larger
resources, and (7) other factors beyond the Company’s control. These
forward-looking statements are made as of the date of this news
release and the Company intends to update such forward looking
information in the Company’s MDA in the event that actual results
differ materially from such forward-looking statements contained
herein. Additional information about these and other assumptions,
risks and uncertainties are set out in the “Risks and Uncertainties”
section in the Company’s MDA filed with Canadian security
regulators.
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Viridis Energy Inc
Michele Rebiere
Chief Financial Officer
905-847-5226
investorinfo@viridisenergy.ca
Grannus Financial Advisors, Inc.
Yvonne L. Zappulla
Managing Director
212-681-4108
Yvonne@GrannusFinancial.com
SOURCE: Viridis Energy Inc.
mailto:investorinfo@viridisenergy.ca
mailto:Yvonne@GrannusFinancial.com
Copyright 2011 Marketwire, Inc., All rights reserved.
/quotes/zigman/561044
![]()
Add VRD to portfolio
CA:VRD

![]()
/quotes/zigman/561044
![]()
Add VRD to portfolio
CA:VRD

![]()
Highwoods Properties Announces $200 Million in Commitments for a New Seven …

RALEIGH, NC, Dec 14, 2011 (MARKETWIRE via COMTEX) –
Highwoods Properties, Inc.
/quotes/zigman/138237/quotes/nls/hiw HIW
+1.31%
today announced that it has
obtained fully executed loan commitments for a new seven-year
unsecured term loan for up to $200 million. The term loan is expected
to mature in the first quarter of 2019 and be prepayable without
penalty beginning in the first quarter of 2016. Based on the
Company’s current credit ratings, the new loan will have an initial
interest rate of LIBOR plus 190 basis points. The Company has
executed forward-starting swaps aggregating $125 million that fix the
underlying LIBOR rate for the seven-year life of the loan at 1.745%.
The net proceeds of the term loan will be used to reduce the
outstanding balance on the Company’s $475 million unsecured revolving
credit facility and for general corporate purposes.
The term loan, which is subject to definitive documentation and
customary conditions, is expected to close within the next 30 days.
Wells Fargo Securities, LLC and PNC Capital Markets LLC are serving
as Lead Arrangers for the term loan.
Ed Fritsch, President and Chief Executive Officer of Highwoods
Properties, said, “We are very appreciative of the continued
confidence shown in Highwoods by the banks who have made commitments
to this planned new term loan. This loan will improve and extend our
debt maturity schedule and further strengthen our ability to
capitalize on acquisition and build-to-suit development opportunities
that enhance long-term value for our shareholders.”
About Highwoods Properties
Highwoods Properties, headquartered in
Raleigh, North Carolina, is a publicly traded
/quotes/zigman/138237/quotes/nls/hiw HIW
+1.31%
real estate
investment trust (“REIT”) and a member of the SP MidCap 400 Index.
The Company is a fully integrated, self-administered REIT that
provides leasing, management, development, construction and other
customer-related services for its properties and for third parties.
At September 30, 2011, Highwoods owned or had an interest in 337
in-service office, industrial and retail properties encompassing
approximately 34.5 million square feet and owned 601 acres of
development land. The Company’s properties and development land are
located in Florida, Georgia, Mississippi, Missouri, North Carolina,
Pennsylvania, South Carolina, Tennessee and Virginia. For more
information about Highwoods Properties, please visit our web site at
www.highwoods.com .
Certain matters discussed in this press release, such as the terms
and timing of anticipated financing activity, are forward-looking
statements within the meaning of the federal securities laws. These
statements are distinguished by use of the words “will”, “expect”,
“intend” and words of similar meaning. Although Highwoods believes
that the expectations reflected in such forward-looking statements
are based upon reasonable assumptions, it can give no assurance that
its expectations will be achieved.
Factors that could cause actual results to differ materially from
Highwoods’ current expectations include, among others, the following:
the financial condition of our customers could deteriorate;
development activity by our competitors in our existing markets could
result in excessive supply of properties relative to customer demand;
development, acquisition, reinvestment, disposition or joint venture
projects may not be completed as quickly or on as favorable terms as
anticipated; we may not be able to lease or re-lease second
generation space quickly or on as favorable terms as old leases; our
markets may suffer declines in economic growth; we may not be able to
lease our newly constructed buildings as quickly or on as favorable
terms as originally anticipated; unanticipated increases in interest
rates could increase our debt service costs; unanticipated increases
in operating expenses could negatively impact our NOI; we may not be
able to meet our liquidity requirements or obtain capital on
favorable terms to fund our working capital needs and growth
initiatives or to repay or refinance outstanding debt upon maturity;
the Company could lose key executive officers; and others detailed in
the Company’s 2010 Annual Report on Form 10-K and subsequent SEC
reports.
SOURCE: Highwoods Properties
Copyright 2011 Marketwire, Inc., All rights reserved.
/quotes/zigman/138237/quotes/nls/hiw
![]()

![]()
/quotes/zigman/138237/quotes/nls/hiw
![]()

![]()
Revett Minerals Announces US$20 Million Revolving Credit Facility With Societe …

SPOKANE VALLEY, WASHINGTON, Dec 12, 2011 (MARKETWIRE via COMTEX) –
Revett Minerals Inc.
/quotes/zigman/1455292 CA:RVM
-4.13%
/quotes/zigman/5056677/quotes/nls/rvm RVM
-4.75%
announced today
that its wholly-owned subsidiary, the Revett Silver Company, has
entered into a revolving credit agreement with Societe Generale as
administrative agent. The US$20 million credit facility is subject to
interest at the London Interbank Offered Rate (“LIBOR”) plus 350
basis points for an initial three year term. The credit facility may
be increased to US$30 million under specified circumstances.
The credit facility may be used for general corporate purposes,
including I Bed development at the Troy Mine, Phase I development at
Rock Creek, and the financing of eligible acquisitions. Letters of
credit issued under the facility may also be used to satisfy
reclamation bonding requirements at the Troy Mine and the Rock Creek
project.
John Shanahan, President and CEO, stated “This credit facility gives
us flexibility as we continue to develop and extend mine life at Troy
and gear ourselves up for development at Rock Creek. It is important
that we fully utilize cash flows from the Troy Mine to seed our next
stage of growth, particularly at current low interest rates. This
credit facility also enables us to enter into the debt markets and
establish a track record as we plan our funding options for Phase II
development of the Rock Creek project.”
Revett Silver Company is the designated borrower under the facility.
Revett Minerals Inc., Troy Mine Inc. and RC Resources, Inc. are
guarantors of the facility. Draws under the facility may be in the
form of revolving credit loans or letters of credit. The facility is
secured by first priority liens and security interests in the
properties and assets comprising the Troy Mine, by Revett Silver
Company’s pledge of the outstanding common stock of Troy Mine Inc.
and RC Resources, Inc., and by Revett Minerals Inc.’s pledge of the
outstanding common stock of Revett Silver Company. No common shares,
options or warrants of Revett Minerals Inc. have been issued to
Societe Generale or any other person in connection with this
agreement.
About Revett
Revett, through its subsidiaries, owns and operates the currently
producing Troy Mine in Lincoln County, Montana and development-stage
Rock Creek Project located in Sanders County, Montana, USA. The
proven reserves at the Troy Mine and significant resources at the
Rock Creek project form the basis of our plan to become a solid
mid-tier base and precious metals producer. Revett plans on expanding
production through exploration in and around its current properties,
as well as through targeted business combinations of advanced stage
projects.
John Shanahan, President CEO
For more information, please visit our website at
www.revettminerals.com .
Except for the statements of historical fact contained herein, the
information presented in this news release may contain
“forward-looking statements” within the meaning of applicable
Canadian securities legislation and The Private Securities Litigation
Reform Act of 1995. Generally, these forward looking statements can
be identified by the use of forward-looking terminology such as
“plans”, “expects”, or “does not expect”, “is expected”, “is not
expected”, “budget”, “plans”, “schedule”, “estimates”, “forecasts”,
“intends”, “anticipates”, “or does not anticipate” or “believes” or
variations of such words and phrases or state that certain actions,
events or results “may”, “could”, “would”, “might” or “will” be
taken, “occur” or “be achieved”. Forward-looking statements contained
in this news release include but are not limited to statements with
respect to drawing upon the revolving credit facility, continued
development and expansion of the Troy Mine and the extension of its
mine life, development of Rock Creek, cash flows from the Troy Mine
being fully utilized to seed development and the financing of
eligible acquisitions. Forward looking statements are subject to
known and unknown risks, uncertainties and other factors. Actual
results and developments could be affected by failing to meet
conditions precedent to draw down on the credit facility, development
risks and production risks, legal challenges and appeals, permitting
requirements, metal prices, the ability of the Company to raise the
necessary financing for development and/or eligible acquisitions and
the ability of the Company to locate eligible acquisitions as well as
those other factors discussed under “Risk Factors” in the Form 10-K
filed on SEDAR at
www.sedar.com and with the SEC on EDGAR. Although
the Company has attempted to identify important factors that could
cause actual results to differ materially, there may be other factors
that cause results not to be as anticipated, estimated or intended.
There can be no assurance that such statements will prove to be
accurate results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not place
undue reliance on forward-looking statements. Revett Minerals does
not undertake to update any forward-looking statements, except in
accordance with applicable securities laws.
Contacts:
Revett Minerals Inc.
Monique Hayes
Corporate Secretary/Investor Relations
(509) 921-2294
(509) 891-8901 (FAX)
www.revettminerals.com
SOURCE: Revett Minerals Inc.
http://www.revettminerals.com
Copyright 2011 Marketwire, Inc., All rights reserved.
/quotes/zigman/1455292
![]()
Add RVM to portfolio
CA:RVM

![]()
/quotes/zigman/5056677/quotes/nls/rvm
![]()

![]()
Mawson West Announces Activities Update

PERTH, AUSTRALIA AND TORONTO, ONTARIO, Nov 21, 2011 (MARKETWIRE via COMTEX) –
Mawson West Ltd.
/quotes/zigman/4486016 CA:MW
+1.27%
(“Mawson” or the “Company”) is pleased
to announce an update on its activities on its 90% owned Dikulushi
Mining Convention located in the Democratic Republic of the Congo
(“DRC”).
Dikulushi Update
At the Dikulushi copper-silver mine, production from the low-grade
stockpile continues, with approximately 350-400 tonnes of copper
(“Cu”) and 30,000-35,000 ounces of silver (“Ag”) being produced per
month. Processing of the stockpile is expected to be completed in
December 2011, after which it is intended that material from
satellite deposits will be processed until ore material from the
Company’s previously announced cut-back expansion project at the
Dikulushi mine is available.
Since acquiring the project from Anvil Mining Limited in April 2010,
Mawson has been exploring within 50km of the Dikulushi processing
plant and has had early success in defining additional deposits that
will supply ore to the plant, with the Company’s aim being to
increase the production life at Dikulushi to 10 years. As a result of
these exploration activities, two additional deposits have been
defined to date. The first is Kazumbula, which is located
approximately 14 km from the Dikulushi mine and which, as previously
disclosed by the Company, has a NI 43-101 compliant indicated
resource of 318 thousand tonnes (“kt”) at a grade of 1.8% Cu and 19
g/t Ag. The second deposit is Boomgate, which is located
approximately 1 km from the Dikulushi mine and for which the Company
has recently calculated an indicated resource of 273kt at a grade of
2.6% Cu and 48g/t Ag and an inferred resource of 233kt at a grade of
1.8% Cu and 25g/t Ag, which is expected to be released in detail by
the end of November 2011. The resource estimate for the Boomgate
deposit is summarised in the tables below (at no cut-off
grade).
-----------------------------------------------------------------------
-----
Cu AsCu Ag
Tonnes Ag Metal Metal metal
Classification Weathering (kt) Density Cu% AsCu% g/t (t) (t) (t)
----------------------------------------------------------------------------
Indicated Oxide 33 2.55 2.48 1.37 49 807 446 51,441
----------------------------------------------------------------------------
Indicated Transition 218 2.6 2.6 1.28 48 5,659 2,799 334,369
----------------------------------------------------------------------------
Indicated Fresh 22 2.6 2.6 1.28 48 734 101 35,366
----------------------------------------------------------------------------
Total Indicated 273 2.59 2.58 1.29 47.84 7,199 3,346 421,000
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Cu AsCu Ag
Tonnes Ag Metal Metal metal
Classification Weathering (kt) Density Cu% AsCu% g/t (t) (t) (t)
----------------------------------------------------------------------------
Inferred Transition 167 2.6 1.27 0.46 14 2,132 762 77,162
----------------------------------------------------------------------------
Inferred Fresh 66 2.6 3.02 0.31 54 1,983 201 112,528
----------------------------------------------------------------------------
Total Inferred 233 2.6 1.77 0.41 25.33 4,115 963 190,000
----------------------------------------------------------------------------
The resource estimate for the Boomgate deposit has been prepared in
accordance with NI 43-101 by David Gray, P. Geo, of Optiro Pty Ltd.,
an independent “Qualified Person”. A NI 43-101 technical report in
respect of the Boomgate deposit resource estimate will be filed under
the Company’s profile on SEDAR.
A further deposit, Golf Course, which is 500 m from the Dikulushi
mine, is in the process of being drilled out.
In addition, the Dikulushi pit cut-back project continues to progress
well. Since the commencement of mining in July 2010, approximately
1.6 million bank cubic metres of waste have been stripped and the
project is on track to deliver first ore to the existing 500,000
tonne per annum processing plant in August 2012. As announced earlier
in the year, in the NI 43-101 Dikulushi cut-back feasibility study,
the Company will recover approximately 2,000t of copper and 200,000oz
of silver per month for an estimated 14 months from the cut-back.
Finally, a feasibility study into reopening the existing underground
development of the Dikulushi deposit will commence in January 2012
and is expected to be completed by the end of 2012. The aim of this
study is to define at least five years of underground mine life.
Kapulo Update
At the Kapulo copper exploration and development project,
construction has commenced. Site civils, including the Pweto-Kapulo
access road upgrade, are well underway. The mine camp is 80%
completed and will be progressed further as more accommodation is
required. Mawson is also building a 600,000t/annum flotation plant
which is anticipated to be producing approximately 18,000t of copper
per annum from the end of 2012.
Exploration Update
Since May 2010, the Company’s exploration programme has been
successful in identifying three new deposits within trucking distance
of the Dikulushi mine, two of which have NI 43-101 compliant
resources (Kazumbula and Boomgate). Several other prospects have
undergone first pass drilling with encouraging results: Kabusanje -
9m @ 2.9% Cu and 167g/t Ag; Kazumbula South – 15m @ 3.0% Cu and 90g/t
Ag; and Lufukwe (previously drilled by Anvil Mining Ltd.) – 10.9m @
2.0% Cu and 103g/t Ag. Geochemical and geophysical surveys have
delineated numerous anomalies, which require follow-up drilling.
The Company’s exploration activities are now beginning to enter the
wet season in the DRC, which extends from November to April, and
during this time most access for regional exploration is difficult
and activities are generally restricted to within close proximity of
existing operations at Dikulushi and Kapulo. Mawson will, however,
endeavour to drill test a number of geophysical targets over the
current wet season. Evaluation of all data collected during the dry
season will continue through the wet.
About Mawson West Ltd.
Mawson West Ltd. is an Australian-based copper producer, developer
and explorer listed on the Toronto Stock Exchange. Mawson’s focus is
on the DRC, and its major asset is its 90% ownership in Anvil Mining
Congo SARL, which is in the process of being renamed CMCC SARL
(“CMCC”). The tenements held by CMCC, comprising 7,300 km2 of
contiguous tenure, encompasses the Company’s two main projects, the
Dikulushi copper-silver mine and the Kapulo copper exploration and
development project, as well as multiple exploration targets. The
tenements held by CMCC are governed by the Dikulushi Mining
Convention.
Mawson’s principal objectives are to expand copper production at the
Dikulushi mine, commence copper production at the Kapulo project and
further explore the area governed by the Dikulushi Mining Convention
to identify new targets. Mawson is also investigating other
opportunities in the DRC and elsewhere which have the capacity to
increase the Company’s production in copper and other metals.
QP Statement
Dave Gray of Optiro and Adam Anderson of Mawson West, both Qualified
Persons for the purposes of National instrument 43-101, have reviewed
and approved the content of this press release.
Forward-Looking Information
This press release contains “forward-looking information” that is
based on Mawson’s expectations, estimates and projections as of the
dates as of which those statements were made. This forward-looking
information includes, among other things, statements with respect to
the Company’s business strategy, plans, outlook, financing plans,
projections, targets and expectations as to reserves, resources,
results of exploration (including targets) and related expenses, mine
development, mine operations, mine production costs, drilling
activity, sampling and other data, estimating grade levels, future
recovery levels, future production levels, capital costs, costs
savings, cash and total costs of production of copper, expenditures
for environmental matters, projected life of Mawson’s mines,
reclamation and other post closure obligations and estimated future
expenditures for those matters, completion dates for the various
development stages of mines, availability of water for milling and
mining, future copper prices (including the long-term estimated
prices used in calculating Mawson’s mineral reserves), end-use demand
for copper, currency exchange rates, timing of expected sales and
final pricing of concentrate sales and anticipated timing of
production at the Dikulushi cut-back project. Generally, this
forward-looking information can be identified by the use of
forward-looking terminology such as “outlook”, “anticipate”,
“project”, “target”, “believe”, “estimate”, “expect”, “intend”,
“should”, “scheduled”, “will”, “plan” and similar expressions.
Forward-looking information is subject to known and unknown risks,
uncertainties and other factors that may cause Mawson’s actual
results, level of activity, performance or achievements to be
materially different from those expressed or implied by such
forward-looking information, and developed based on assumptions about
such risks, uncertainties and other factors set out herein, including
but not limited to:
-- Our ability to successfully bring the Dikulushi cut-back project into
production;
-- Receipt of all permits required for the Dikulushi cut-back project;
-- The ability of our key contractors to perform the services for us in the
manner contracted for;
-- The availability and cost of key operating supplies and services;
-- The production facilities may not achieve the planned desired
recoveries;
-- Fluctuations in copper prices;
-- Insurance coverage may not be available for certain risks that the
company might deem it prudent to insure against;
-- The ability to expand or replace depleted reserves and the possible
recalculation or reduction of the reserves and resources;
-- Actual capital costs, operating costs and expenditures, production
schedules and economic returns from the Dikulushi cut-back project;
-- Geotechnical issues;
-- Mineralogy and block model assumptions;
-- Potential challenges to title to the properties;
-- Inherent hazards and risks associated with mining operations;
-- Inherent uncertainties associated with mineral exploration;
-- Being subject to government regulation, including changes in regulation;
-- Being subject to extensive environmental laws and regulations, including
change in regulation;
-- Need for governmental licenses and permits;
-- Political and country risk;
-- Fluctuations in foreign currency exchange rates; and
-- Global financial conditions.
Forward-looking statements are based on assumptions management believes
to be reasonable, including but not limited to no material adverse
change in the market price of commodities, that mining development
and operations will operate in accordance with Mawson’s public
statements and achieve their stated outcomes, and such other
assumptions and factors as set out herein. Although Mawson has
attempted to identify important factors that could cause actual
results to differ materially from those contained in forward-looking
statements, there may be other factors that cause results not to be
as anticipated, estimated or intended. There can be no assurance that
forward-looking statements will prove to be accurate. Accordingly,
readers should not place undue reliance on forward-looking
statements. Mawson disclaims any intent or obligations to update or
revise publicly any forward-looking statements whether as a result of
new information, estimates or options, future events or results or
otherwise, unless required to do so by law.
To view the Kapulo Camp Accommodation, please visit the following
link:
http://media3.marketwire.com/docs/KapuloCampAccommodation.pdf .
To view the Pweto-Kapulo Road, please visit the following link:
http://media3.marketwire.com/docs/Pweto.pdf .
To view the Dikulushi Cut Back, please visit the following link:
http://media3.marketwire.com/docs/DikulushiCutBack.pdf .
Contacts:
Mawson West Ltd.
David Frances
President and Chief Executive Officer
61 8 9321-9669
61 8 9481-2394 (FAX)
dfrances@mawsonwest.com
SOURCE: Mawson West Ltd.
mailto:dfrances@mawsonwest.com
Copyright 2011 Marketwire, Inc., All rights reserved.
/quotes/zigman/4486016
![]()
Add MW to portfolio
CA:MW

![]()
CryoPort Announces Letter to Shareholders Posted to Website

SAN DIEGO, Nov 14, 2011 (BUSINESS WIRE) –
CryoPort, Inc.
/quotes/zigman/586363 CYRX
+5.75%
today announced that the following Letter
to Shareholders will be posted today to the investor relations section
of the Company’s website at
www.cryoport.com .
In addition, today the Company filed with the U.S. Securities and
Exchange Commission its Quarterly Report for the three and six
months ended September 30, 2011 on Form 10-Q. The Form 10-Q includes
unaudited interim consolidated financial statements, as well as
additional information regarding the Company. The Form 10-Q is available
at
www.sec.gov
or
www.cryoport.com .
November 14, 2011
To Our Shareholders:
As we report mid-year fiscal 2012 financial results for CryoPort, I am
pleased to provide you with an update on our operations and activities,
and discuss key developments that have taken place in recent months.
We have made significant progress in several important areas including
building our sales and marketing infrastructure, forming strategic
partnerships, creating industry awareness and developing a pipeline of
potential new customers. Our focus over the past several months has been
on commercializing the CryoPort Express(R) Dry Vapor Shipping
solution for the global life sciences industry, and I am more confident
than ever that the combination of our patented shipping container with
our turnkey, web-based ordering and shipping process is a superior
alternative to the outdated industry standard of dry-ice shipping. My
confidence is bolstered by the positive reception this solution is
getting from potential customers we call on.
Our sales and marketing operation has grown from one person at the
beginning of 2011 to now include a new senior director of marketing, as
well as four U.S. senior sales directors located in key regional markets
and a European senior sales director under the leadership of our chief
commercial officer, Mark Engelhart. In response to demand from
healthcare companies, we are establishing an operations center in The
Netherlands to develop and serve our growing market. We have also added
Cindy Gick as vice president of client care and development to provide
around-the-clock client support for customers worldwide. In addition to
expanded marketing and operational capabilities, we bolstered the
executive team in June with the addition of Robert Stefanovich as chief
financial officer.
Our strategic partnership with FedEx commenced operations earlier this
year and FedEx has shown a strong commitment to CryoPort with its
customer representatives introducing the CryoPort Express(R) Dry
Shipper-based FedEx Deep Frozen Shipping Solution to a wide range of
organizations.
Earlier in the year, we completed the integration of our sophisticated
order entry and tracking web portal with DHL’s ordering and billing
systems, thereby allowing DHL’s life science customers around the world
to order directly from CryoPort and receive preferred DHL shipping rates.
Our technology is disruptive to an industry standard that has been in
place for decades. Yet importantly, the life sciences industry is
heavily regulated and prospective customers generally require a lengthy
evaluation and validation process prior to the adoption or our solution.
What is most encouraging is the positive response we are receiving after
presenting all the benefits and features of the CryoPort solution.
Several companies have now successfully completed their on-boarding
process.
Two examples illustrate the complexity of our sales on-boarding cycle:
–
ImClone Systems, a leading developer of cancer therapeutics, recently
completed the process of “vendor qualification” for CryoPort. The
process began several months ago with an extensive audit of our
manufacturing and refurbishing process and a review of our standard
operating procedures. It also involved several departments at ImClone
— including Research Development, Clinical Trials, Supply Chain
Logistics and Quality Assurance/Quality Control — as well as test
shipments to designated locations. Now that we are a qualified vendor,
ImClone Systems commenced shipping with CryoPort in October this year.
–
One of the largest central labs serving clinical trials, ACM Global,
recently introduced the CryoPort solution to its customers following a
six-month review. During their review ACM was able to confirm that
Cryoport’s dry-vapor technology was in compliance with the stringent
global regulatory standards and stable temperature profiles needed to
ensure specimen viability. As part of ACM’s comprehensive validation
effort, the company assessed the movement and temperature profile of
almost 600 unique specimens over a multitude of shipping lanes,
including international clinical trial hubs in India, China, Southeast
Asia and Europe.
Although the evaluation process is intensive, upon completion it
establishes a presumed strong and long-term partnership with the
customer. Across industry groups, including biotechnology and
pharmaceutical companies, diagnostic labs, contract research
organizations, clinical trial providers and major medical centers, we
currently have more than 50 organizations at various stages of
evaluating CryoPort as their potential shipping partner. We have also
identified additional vertical markets, such as in vitro
fertilization clinics and stem cell development firms, which place a
premium on maintaining specimen integrity in transit. Sigma Aldrich is
among those companies that have recently adopted the CryoPort frozen
shipping solution, after several months of evaluation, for their key
stem cell shipping needs.
Throughout the year we have seen the deep frozen shipping market in
healthcare continue to grow due to the globalization of clinical trials
and an increase in development of biological drugs. In addition, the
need to upgrade shipping and logistics standards has become an important
industry topic. I am pleased to report that within that context, the
CryoPort solution has a significantly higher profile and industry
awareness than just six months ago. In addition to direct customer
contact, we have participated in several industry conferences and
tradeshows worldwide. In just the last two months, CryoPort senior
executives have attended and presented at nine industry events, which
included the largest conferences on global pharmaceutical logistics.
Our awareness effort has been augmented by the work of Rafik Bishara,
Ph.D., who joined our advisory board in August. Dr. Bishara is the
current Chair of the Pharmaceutical Cold Chain Interest Group,
Parenteral Drug Association, and is considered one of the world’s
leading experts in cold chain distribution and shipping of
pharmaceutical products and life science materials. Dr. Bishara is
already playing an important role in identifying new market
opportunities and presenting the CryoPort solution to key audiences.
With our recent progress and the commercial team in place, CryoPort is
positioned to further penetrate the life science and healthcare market,
significantly expand our commercial operations and pursue our goal of
becoming the industry standard in deep frozen global shipping.
On behalf of everyone at CryoPort, I thank you for your continued
support.
Sincerely,
Larry Stambaugh
President and Chief Executive Officer
Certain of the statements herein may be forward-looking and involve
risks and uncertainties. Such forward-looking statements involve
assumptions, known and unknown risks, uncertainties and other factors
that may cause the actual results, performance or achievements of
CryoPort, Inc. to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Actual results could differ materially as a result of a
variety of factors, including the risks associated with the effect of
changing economic conditions and other risk factors detailed in the
Company’s Securities and Exchange Commission filings, including its most
recent annual report on Form 10-K for the year ended March 31, 2011.
About CryoPort, Inc.
CryoPort (
www.cryoport.com )
provides leading edge cold chain logistics services through the
combination of purpose built proprietary technologies and total turnkey
management of the entire process. CryoPort’s CryoPort Express liquid
nitrogen based dry vapor shipper is validated to maintain a constant
-150 C temperature for a minimum 10 day dynamic shipment duration, and
its CryoPortal Logistics Management Platform manages the entire shipment
process, including initial order, document preparation, customs
clearance, courier management, shipment tracking, issue resolution,and
delivery. CryoPort’s total turnkey service management approach offers
total reliability, cost effectiveness, and convenience, while the use of
recyclable and reuseable components provides a totally “green” and
environmentally friendly solution. For more information visit
www.cryoport.com
and the Cold Chain Transport blog at
http://www.cryoport.com/biological-shipping-blog/
SOURCE: CryoPort, Inc.
LHA
Don Markley, 310-691-7100
dmarkley@lhai.com
Copyright Business Wire 2011
/quotes/zigman/586363
![]()

![]()

Goldcorp secures certificate of authorization for construction of Éléonore Project

VANCOUVER, Nov. 14, 2011 /PRNewswire via COMTEX/ –
Toronto Stock Exchange: G New York Stock Exchange: GG
(All Amounts in $US unless stated otherwise)
GOLDCORP INC.
/quotes/zigman/22920 CA:G
-1.23%
/quotes/zigman/22897/quotes/nls/gg GG
-1.80%
today announced that a certificate of authorization has been issued by
the Quebec Minister of Sustainable Development, Environment and Parks
allowing full construction of the Éléonore gold project in northern
Quebec to commence immediately.With life-of-mine gold production
expected to average approximately 600,000 ounces of gold per year,
Éléonore will be one of the largest underground gold mines in Canada
and a key element of Goldcorp’s leading growth profile.
“Receipt of approvals for construction at Éléonore ensures that the
strong pace of development will continue at this pure gold project,”
said Chuck Jeannes, Goldcorp President and Chief Executive Officer.
“With robust, low-cost gold production in the heart of one of the most
attractive mining jurisdictions in the world, Éléonore is well
positioned as one of Goldcorp’s future cornerstone assets.A strong,
experienced team is already in place and we remain on track for first
gold production in late 2014.”
Issuance of the certificate of authorization follows the execution of
the collaboration agreement among the Cree Nation of
Wemindji,theGrand Council of the Crees(Eeyou Istchee), theCree
Regional Authority(the “Cree”)and the Company earlier this year.
“Oursolid relationship with the Cree and the timely processing of the
application by the government of Quebec were essential to achieving
this next step toward our common interest in constructing and operating
what we believe will be the best new gold mine in Canada,” added
Jeannes.
The current Éléonore development plan details an average throughput rate
of 7,000 tonnes per day, contributing to the forecast average 600,000
ounces of gold production per year at cash costs below $400 per ounce
over an approximate 15-year mine life.Total capital cost is expected
to be approximately $1.4 billion to full production.
Significant progress has already been achieved at the site. The
exploration shaft has advanced to a depth of 588 metres, with
completion to full 725-metre depth on track for the second quarter of
2012.The exploration ramp has reached 663 metres in length and will
provide drilling locations for further resource definition as mine
development progresses.The receipt of the certificate of authorization
now allows for the commencement of construction of the second
production shaft and related infrastructure, as well as the 7000 tonne
per day process facility, the 63-kilometre access road and the 120 Kv
electrical sub-station.
Goldcorp is one of the world’s fastest growing senior gold
producers.Its low-cost gold production is located in safe
jurisdictions in the Americas and remains 100% unhedged.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements”, within the
meaning of the United States Private Securities Litigation Reform Act
of 1995 and applicable Canadian securities legislation, concerning the
business, operations and financial performance and condition of
Goldcorp Inc. (“Goldcorp”). Forward-looking statements include, but are
not limited to, statements with respect to the future price of gold,
silver, copper, lead and zinc, the estimation of mineral reserves and
resources, the realization of mineral reserve estimates, the timing and
amount of estimated future production, costs of production, capital
expenditures, costs and timing of the development of new deposits,
success of exploration activities, permitting time lines, hedging
practices, currency exchange rate fluctuations, requirements for
additional capital, government regulation of mining operations,
environmental risks, unanticipated reclamation expenses, timing and
possible outcome of pending litigation, title disputes or claims and
limitations on insurance coverage. Generally, these forward-looking
statements can be identified by the use of forward-looking terminology
such as “plans”, “expects”, “is expected”, “budget”, “scheduled”,
“estimates”, “forecasts”, “intends”, “anticipates”, “believes” or
variations of such words and phrases or statements that certain
actions, events or results “may”, “could”, “would”, “might” or “will be
taken”, “occur” or “be achieved” or the negative connotation thereof.
Forward-looking statements are made based upon certain assumptions and
other important factors that, if untrue, could cause the actual
results, performances or achievements of Goldcorp to be materially
different from future results, performances or achievements expressed
or implied by such statements.Such statements and information are
based on numerous assumptions regarding present and future business
strategies and the environment in which Goldcorp will operate in the
future, including the price of gold, anticipated costs and ability to
achieve goals. Certain important factors that could cause actual
results, performances or achievements to differ materially from those
in the forward-looking statements include, among others, gold price
volatility, discrepancies between actual and estimated production,
mineral reserves and resources and metallurgical recoveries, mining
operational and development risks, litigation risks, regulatory
restrictions (including environmental regulatory restrictions and
liability), activities by governmental authorities (including changes
in taxation), currency fluctuations, the speculative nature of gold
exploration, the global economic climate, dilution, share price
volatility, competition, loss of key employees, additional funding
requirements and defective title to mineral claims or
property.Although Goldcorp has attempted to identify important factors
that could cause actual actions, events or results to differ materially
from those described in forward-looking statements, there may be other
factors that cause actions, events or results not to be as anticipated,
estimated or intended.
Forward-looking statements are subject to known and unknown risks,
uncertainties and other important factors that may cause the actual
results, level of activity, performance or achievements of Goldcorp to
be materially different from those expressed or implied by such
forward-looking statements, including but not limited to: risks related
to the integration of acquisitions; risks related to international
operations, including economical and political instability in foreign
jurisdictions in which Goldcorp operates; risks related to current
global financial conditions; risks related to joint venture operations;
actual results of current exploration activities; environmental risks;
future prices of gold, silver, copper, lead and zinc; possible
variations in ore reserves, grade or recovery rates; mine development
and operating risks; accidents, labour disputes and other risks of the
mining industry; delays in obtaining governmental approvals or
financing or in the completion of development or construction
activities; risks related to indebtedness and the service of such
indebtedness, as well as those factors discussed in the section
entitled “Description of the Business – Risk Factors” in Goldcorp’s
annual information form for the year ended December 31, 2010 available at
www.sedar.com . Although Goldcorp has attempted to identify important factors that
could cause actual results to differ materially from those contained in
forward-looking statements, there may be other factors that cause
results not to be as anticipated, estimated or intended.There can be
no assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements.Accordingly, readers should not place
undue reliance on forward-looking statements. Forward-looking
statements are made as of the date hereof and accordingly are subject
to change after such date. Except as otherwise indicated by Goldcorp,
these statements do not reflect the potential impact of any
non-recurring or other special items or of any dispositions,
monetizations, mergers, acquisitions, other business combinations or
other transactions that may be announced or that may occur after the
date hereof.Forward-looking statements are provided for the purpose of
providing information about management’s current expectations and plans
and allowing investors and others to get a better understanding of our
operating environment. Goldcorp does not undertake to update any
forward-looking statements that are included in this document, except
in accordance with applicable securities laws.
SOURCE Goldcorp Inc.
Copyright (C) 2011 PR Newswire. All rights reserved
/quotes/zigman/22920
![]()
Add G to portfolio
CA:G

![]()
/quotes/zigman/22897/quotes/nls/gg
![]()

![]()

Celldex Therapeutics Announces Orphan Drug Designation in the European Union …

NEEDHAM, Mass., Oct 31, 2011 (BUSINESS WIRE) –
Celldex Therapeutics, Inc.
/quotes/zigman/112431/quotes/nls/cldx CLDX
+2.64%
today announced that the
European Medicines Agency (EMA) has granted orphan drug designation for
rindopepimut for the treatment of Glioblastoma (GB). GB is the most
common and aggressive form of brain cancer. Rindopepimut is an
immunotherapy that targets the tumor-specific oncogene (a growth
promoter), EGFRvIII.
“Obtaining orphan designation for rindopepimut in the European Union
(EU) is an important regulatory milestone for Celldex,” said Anthony S.
Marucci, President and Chief Executive Officer of Celldex Therapeutics.
“The benefits include 10 years of market exclusivity from product launch
in the EU, fee reductions, as well as access to the central
authorization procedure. We have already been granted Orphan Drug
designation for this program by the FDA, which allows for 7 years of
market exclusivity from product launch in the U.S. as well as Fast Track
designation to accelerate the review of rindopepimut.”
“These orphan drug designations support our global development strategy
for rindopepimut and our goal of providing improved therapies for
patients with EGFRvIII positive glioblastoma,” said Dr. Thomas Davis,
Senior Vice President and Chief Medical Officer of Celldex Therapeutics.
“Our clinical experience to date with rindopepimut has demonstrated its
potential in prolonging overall survival in front-line EGFRvIII
expressing glioblastoma, where limited treatment options exist. This
activity, paired with a favorable safety profile, underpins our plans to
move forward with the initiation of a Phase 3 study of this program by
year-end 2011.”
After consultations with both U.S. and EU regulatory authorities,
Celldex has finalized the clinical protocol for the Phase 3 randomized,
double-blind study of rindopepimut in GB. The primary endpoint of the
study will be overall survival. The study, named ACT IV, is expected to
enroll up to 374 patients with newly-diagnosed, fully resected, EGFRvIII
expressing GB from over 150 clinical sites internationally. Enrollment
is expected to begin in the fourth quarter of 2011.
Also during the fourth quarter of 2011, Celldex expects to initiate a
Phase 2 randomized study of rindopepimut in combination with Avastin(R)
in recurrent or refractory GB patients with EGFRvIII expression (the
ReACT study). The ReACT study is expected to enroll up to 95 patients in
the U.S. and will evaluate objective response rates (ORR), progression
free survival (PFS) and overall survival (OS) endpoints in this patient
population.
EMA’s Orphan Medicinal Product Designation is designed to promote the
development of drugs that may provide significant benefit to patients
suffering from rare, life-threatening diseases. In addition to 10 years
of market exclusivity if rindopepimut is approved for the treatment of
GB, the designation also provides special incentives for sponsors
including eligibility for protocol assistance and possible exemptions or
reductions in certain regulatory fees during development or at the time
of application for marketing approval.
Similarly, FDA orphan drug designation is intended to encourage
companies to develop therapies for the treatment of diseases that affect
fewer than 200,000 individuals in the United States. This designation
will provide Celldex Therapeutics with 7 years of marketing exclusivity
for rindopepimut in EGFRvIII positive GB if rindopepimut is approved by
the FDA in such indication. Prior to FDA approval, orphan designation by
the FDA provides the opportunity to obtain grant funding to defray costs
of clinical trial expenses, tax credits for clinical research expenses
and potential waiver of the FDA’s application user fees.
About Rindopepimut
Rindopepimut is an investigational immunotherapy that targets the tumor
specific molecule EGFRvIII, a functional variant of the epidermal growth
factor receptor (EGFR), which is a protein that has been well validated
as a target for cancer therapy. This particular variant, EGFRvIII,
occurs in about 30 percent of glioblastoma patients. Unlike EGFR,
EGFRvIII is not present in normal tissues suggesting this target will
enable the development of a tumor- specific therapy for cancer patients.
Furthermore, EGFRvIII is a transforming oncogene that can directly
contribute to cancer cell growth. While originally discovered in GB, the
most common and aggressive form of brain cancer, the expression of
EGFRvIII has also been observed in various other cancers such as breast,
ovarian, metastatic prostate, colorectal, and head neck cancers.
Celldex has exclusive rights to EGFRvIII vaccines and is pursuing the
development of rindopepimut for GB therapy, as well as for other cancers
through additional clinical studies.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination
immunotherapy company. Celldex has a pipeline of drug candidates in
development for the treatment of cancer and other difficult-to-treat
diseases based on its antibody focused Precision Targeted Immunotherapy
(PTI) Platform. The PTI Platform is a complementary portfolio of
monoclonal antibodies, antibody-targeted vaccines and immunomodulators
used in optimal combinations to create novel disease-specific drug
candidates. For more information, please visit
http://www.celldextherapeutics.com .
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995: This release contains “forward-looking
statements” made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, including those related to the
Company’s strategic focus and the future development and
commercialization (by Celldex and others) of rindopepimut (CDX-110),
CDX-011, CDX-1135 (formerly TP10), CDX-1401, CDX-1127, CDX-301,
Belinostat and other products. Forward-looking statements reflect
management’s current knowledge, assumptions, judgment and expectations
regarding future performance or events. Although management believes
that the expectations reflected in such statements are reasonable, they
give no assurance that such expectations will prove to be correct and
you should be aware that actual results could differ materially from
those contained in the forward-looking statements. Forward-looking
statements are subject to a number of risks and uncertainties,
including, but not limited to, our ability to obtain additional capital
on acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials that we plan to
initiate in 2011; our ability to adapt APC Targeting Technology(TM)
to develop new, safe and effective vaccines against oncology and
infectious disease indications; our ability to successfully complete
product research and further development of our programs; the
uncertainties inherent in clinical testing; our limited experience in
bringing programs through Phase 3 clinical trials; our ability to manage
research and development efforts for multiple products at varying stages
of development; the timing, cost and uncertainty of obtaining regulatory
approvals; the failure of the market for the Company’s programs to
continue to develop; our limited cash reserves and our ability to obtain
additional capital on acceptable terms, or at all; our ability to
protect the Company’s intellectual property; the loss of any executive
officers or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect the
Company’s products; and other risks detailed from time to time in the
Company’s filings with the Securities and Exchange Commission, including
the Company’s Form 10-K for the fiscal year ended December 31, 2010,
and its Forms 10-Q and 8-K.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You are cautioned not to place undue
reliance on any forward-looking statements, which speak only as of the
date of this release. We have no obligation, and expressly disclaim any
obligation, to update, revise or correct any of the forward-looking
statements, whether as a result of new information, future events or
otherwise.
SOURCE: Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
Anthony S. Marucci, 781-433-0771
President and CEO
or
Celldex Therapeutics, Inc.
Avery W. Catlin, 781-433-0771
IR@celldextherapeutics.com
or
For Media:
BMC Communications
Brad Miles, 212-477-9007 x17
Chief Financial Officer
brad@bmccommunications.com
Copyright Business Wire 2011
/quotes/zigman/112431/quotes/nls/cldx
![]()

![]()

PharmaGap Sets Time for in Vivo Tests

OTTAWA, ONTARIO, Oct 27, 2011 (MARKETWIRE via COMTEX) –
PharmaGap Inc.
/quotes/zigman/303449 CA:GAP
0.00%
/quotes/zigman/303450 PHRGF
+45.08%
(“PharmaGap” or “the
Company”) reported today that in vivo (“in life”) efficacy testing of
its GAP-107B8 cancer drug, in original, enhanced and liposome
formulated versions, is scheduled to begin on or about November 13,
2011. In this efficacy study, the PharmaGap drug compounds will be
tested in validated mouse models for ovarian cancer, using 3 human
ovarian cancer cell lines across a total of 168 mice including
treated and control groups. The treatment periods for the three cell
lines will be staggered, and will run through the third week of
December.
Prior to this, the Company will undertake a Maximum Tolerated Dose
(“MTD”) study in order to finalize the dose level range for the
efficacy study. The MTD study will evaluate the tolerability of
PharmaGap’s formulations in a repeat dosing design suitable for use
in efficacy models and is scheduled to begin on October 28.
Following the treatment period, compilation of all data, including
in-life observations along with histology and pathology examination
observations will be analyzed in order to inform the Company as to
the preferred formulation of GAP-107B8 with which to proceed to
clinical trials.
While this test program is undertaken, the Company is proceeding
aggressively in discussions with candidates for its cGMP (“current
Good Manufacturing Practices) manufacturing development program, and
with clinical trial contract research organizations for development
(and eventual delivery) of protocols for PharmaGap’s first clinical
trial. These three elements (in vivo efficacy results, manufacturing,
and clinical trial protocol) will converge to provide the basis to
undertake the required GLP (Good Laboratory Practices”) Toxicology
program using cGMP grade material, and to the continued generation
and compilation of all data required for inclusion in its clinical
trial application.
About PharmaGap Inc.
PharmaGap Inc.
/quotes/zigman/303449 CA:GAP
0.00%
, based in Ottawa, ON, is a
biotechnology company with a core focus on developing novel peptide
therapeutics for the treatment of cancer. PharmaGap’s GAP-107B8 is a
novel peptide drug that has been shown to be highly cytotoxic to
numerous cancer types, including chemo-resistant cancers, in vitro.
For more information on PharmaGap please visit the Company’s website
at
www.pharmagap.com .
Forward Looking Statements
This news release contains certain statements that constitute
forward-looking statements as they relate to the Company and its
management. Forward-looking statements are not historical facts but
represent management’s current expectations of future events, and can
be identified by words such as “believe”, “expects”, “will”,
“intends”, “plans”, “projects”, “anticipates”, “estimates”,
“continues”, and similar expressions. Although management believes
that expectations represented in such forward-looking statements are
reasonable, there can be no assurance that they will prove to be
correct.
By their nature, forward-looking statements include assumptions and
are subject to inherent risks and uncertainties that could cause
actual future results, conditions, actions or events to differ
materially from those in the forward-looking statements. If and when
forward-looking statements are set out in this news release,
PharmaGap will also set out the material risk factors or assumptions
used to develop the forward-looking statements. Except as expressly
required by applicable securities laws, the Company assumes no
obligation to update or revise any forward-looking statements. The
future outcomes that relate to forward-looking statements may be
influenced by many factors, including, but not limited to: results of
ongoing product testing and development; regulatory approvals
required to complete development of products; ability to manufacture
product at quality and scale for human use on an economically sound
basis; patient reimbursement by private and public health insurance
programs; unintended side effects of products; competitive products;
product liability; intellectual property; reliance on key personnel;
risks of future legal proceedings; income tax matters; availability
and terms of financing; distribution of securities; effect of market
interest rates on price of securities, and potential dilution.
Note: Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this
release. No Securities Commission or other regulatory authority
having jurisdiction over PharmaGap has approved or disapproved of the
information contained herein. This release contains forward looking
statements that may not occur or may change materially.
Contacts:
PharmaGap Inc.
Robert McInnis
President CEO
613-990-9551
bmcinnis@pharmagap.com
SOURCE: PharmaGap Inc.
mailto:bmcinnis@pharmagap.com
Copyright 2011 Marketwire, Inc., All rights reserved.
/quotes/zigman/303449
![]()
Add GAP to portfolio
CA:GAP

![]()
/quotes/zigman/303450
![]()
Add PHRGF to portfolio
PHRGF

![]()
/quotes/zigman/303449
![]()
Add GAP to portfolio
CA:GAP

![]()

